Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma

Both the combination of nivolumab + ipilimumab and single‐agent anti‐PD‐1 immunotherapy have demonstrated survival benefit for patients with advanced melanoma. As the combination has a high rate of serious side effects, further analyses in randomized trials of combination versus anti‐PD‐1 immunother...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Med
Asıl Yazarlar: Rosner, Samuel, Kwong, Erica, Shoushtari, Alexander N., Friedman, Claire F., Betof, Allison S., Brady, Mary Sue, Coit, Daniel G., Callahan, Margaret K., Wolchok, Jedd D., Chapman, Paul B., Panageas, Katherine S., Postow, Michael A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2018
Konular:
Clinical Cancer Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5852343/
https://ncbi.nlm.nih.gov/pubmed/29468834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1356
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller